blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1446012

EP1446012 - COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.05.2014
Database last updated on 25.09.2024
Most recent event   Tooltip24.07.2015Lapse of the patent in a contracting state
New state(s): BG, LU		published on 26.08.2015  [2015/35]
Applicant(s)For all designated states
The Johns Hopkins University
School of Medicine
111 Market Place, Suite 906
Baltimore, MD 21202 / US
[2013/10]
Former [2004/34]For all designated states
The Johns Hopkins University School of Medicine
Suite 906, 111 Market Place
Baltimore, MD 21202 / US
Inventor(s)01 / DANG, Long
2225 Rogene Drive
No. 101
Baltimore, MD 21209 / US
02 / KINZLER, Kenneth, W.
1403 Halkirk Way
Bel Air, MD 21015 / US
03 / VOGELSTEIN, BERT
3700 Breton Way
Baltimore, MD 21208 / US
 [2013/10]
Former [2004/34]01 / DANG, Long
2225 Rogene Drive, 101
Baltimore, MD 21209 / US
02 / KINZLER, Kenneth, W.
1403 Halkirk Way
Bel Air, MD 21015 / US
03 / VOGELSTEIN, BERT
3700 Breton Way
Baltimore, MD 21208 / US
Representative(s)Tombling, Adrian George, et al
Withers & Rogers LLP
2 London Bridge
London SE1 9RA / GB
[N/P]
Former [2013/29]Tombling, Adrian George, et al
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Former [2004/34]Tombling, Adrian George, et al
Withers & Rogers Goldings House 2 Hays Lane
London SE1 2HW / GB
Application number, filing date02786766.221.11.2002
[2004/34]
WO2002US37509
Priority number, dateUS20010331786P21.11.2001         Original published format: US 331786 P
[2004/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03045153
Date:05.06.2003
Language:EN
[2003/23]
Type: A1 Application with search report 
No.:EP1446012
Date:18.08.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 05.06.2003 takes the place of the publication of the European patent application.
[2004/34]
Type: B1 Patent specification 
No.:EP1446012
Date:17.07.2013
Language:EN
[2013/29]
Search report(s)International search report - published on:US05.06.2003
(Supplementary) European search report - dispatched on:EP29.01.2007
ClassificationIPC:A61K35/74, A61K38/05, A61K31/40, A61K31/675, A61P35/00, C12N1/20, C12R1/145
[2013/09]
CPC:
A61K31/475 (EP,US); C12N1/205 (EP,US); A61K35/742 (EP,US);
A61K38/193 (EP,US); A61K41/00 (EP,US); A61K45/06 (EP,US);
A61P35/00 (EP); C12N1/36 (EP,US); C12R2001/145 (EP,US) (-)
C-Set:
A61K31/475, A61K2300/00 (EP,US);
A61K35/742, A61K2300/00 (US,EP);
A61K38/193, A61K2300/00 (US,EP);
A61K41/00, A61K2300/00 (US,EP)
Former IPC [2007/01]C12N1/20, A61K35/66, A61K35/74
Former IPC [2004/34]A01N63/00, A01N65/00, A61K48/00, C12N1/12, C12N1/20, G01N33/53
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2004/34]
TitleGerman:BAKTERIOLYTISCHE KOMBINATIONSTHERAPIE FÜR DIE BEHANDLUNG VON TUMOREN[2004/34]
English:COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS[2004/34]
French:THERAPIE BACTERIOLYTIQUE COMBINEE POUR LE TRAITEMENT DE TUMEURS[2004/34]
Entry into regional phase21.05.2004National basic fee paid 
21.05.2004Search fee paid 
21.05.2004Designation fee(s) paid 
21.05.2004Examination fee paid 
Examination procedure18.06.2003Request for preliminary examination filed
International Preliminary Examining Authority: US
21.05.2004Examination requested  [2004/52]
25.03.2008Despatch of a communication from the examining division (Time limit: M06)
24.09.2008Reply to a communication from the examining division
03.09.2009Despatch of a communication from the examining division (Time limit: M04)
21.12.2009Reply to a communication from the examining division
05.08.2010Despatch of a communication from the examining division (Time limit: M04)
06.12.2010Reply to a communication from the examining division
27.09.2011Despatch of a communication from the examining division (Time limit: M04)
18.11.2011Reply to a communication from the examining division
06.02.2013Communication of intention to grant the patent
06.06.2013Fee for grant paid
06.06.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.03.2008
Opposition(s)22.04.2014No opposition filed within time limit [2014/26]
Fees paidRenewal fee
12.11.2004Renewal fee patent year 03
26.01.2006Renewal fee patent year 04
14.11.2006Renewal fee patent year 05
15.11.2007Renewal fee patent year 06
12.11.2008Renewal fee patent year 07
27.11.2009Renewal fee patent year 08
24.11.2010Renewal fee patent year 09
23.11.2011Renewal fee patent year 10
26.11.2012Renewal fee patent year 11
Penalty fee
Additional fee for renewal fee
30.11.200504   M06   Fee paid on   26.01.2006
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT17.07.2013
BE17.07.2013
BG17.07.2013
CY17.07.2013
CZ17.07.2013
EE17.07.2013
FI17.07.2013
MC17.07.2013
SE17.07.2013
SK17.07.2013
GR18.10.2013
PT18.11.2013
IE21.11.2013
LU21.11.2013
CH30.11.2013
LI30.11.2013
[2015/34]
Former [2014/48]AT17.07.2013
BE17.07.2013
CY17.07.2013
CZ17.07.2013
EE17.07.2013
FI17.07.2013
MC17.07.2013
SE17.07.2013
SK17.07.2013
GR18.10.2013
PT18.11.2013
IE21.11.2013
CH30.11.2013
LI30.11.2013
Former [2014/34]AT17.07.2013
BE17.07.2013
CY17.07.2013
CZ17.07.2013
EE17.07.2013
FI17.07.2013
MC17.07.2013
SE17.07.2013
SK17.07.2013
GR18.10.2013
PT18.11.2013
CH30.11.2013
LI30.11.2013
Former [2014/33]AT17.07.2013
BE17.07.2013
CY17.07.2013
CZ17.07.2013
EE17.07.2013
FI17.07.2013
MC17.07.2013
SE17.07.2013
SK17.07.2013
GR18.10.2013
PT18.11.2013
Former [2014/23]AT17.07.2013
BE17.07.2013
CY17.07.2013
CZ17.07.2013
EE17.07.2013
FI17.07.2013
SE17.07.2013
SK17.07.2013
GR18.10.2013
PT18.11.2013
Former [2014/18]AT17.07.2013
BE17.07.2013
CY17.07.2013
FI17.07.2013
SE17.07.2013
GR18.10.2013
PT18.11.2013
Former [2014/12]CY03.07.2013
AT17.07.2013
BE17.07.2013
FI17.07.2013
SE17.07.2013
GR18.10.2013
PT18.11.2013
Former [2014/11]CY03.07.2013
AT17.07.2013
BE17.07.2013
FI17.07.2013
SE17.07.2013
PT18.11.2013
Former [2014/10]CY03.07.2013
AT17.07.2013
BE17.07.2013
SE17.07.2013
PT18.11.2013
Former [2014/09]AT17.07.2013
BE17.07.2013
SE17.07.2013
PT18.11.2013
Former [2014/08]PT18.11.2013
Documents cited:Search[DXY]  - EKLUND M W ET AL, "Relationship of bacteriophages to alpha toxin production in Clostridium novyi types A and B.", INFECTION AND IMMUNITY. SEP 1976, (197609), vol. 14, no. 3, ISSN 0019-9567, pages 793 - 803, XP002405800 [DX] 1-9 * abstract * * page 793, column 1, paragraph 1 - column 2, paragraph 2 * * page 795; table 2 * * page 800, column 2, paragraph 3 - page 802, column 1, paragraph 3 * [Y] 10-52
 [DXY]  - EKLUND M W ET AL, "Interspecies conversion of clostridium botulinum type C to clostridium novyi type A by bacteriophage", SCIENCE 1974, (1974), vol. 186, no. 4162, pages 456 - 458, XP002405801 [DX] 1-9 * abstract * * page 456, column 3, paragraph 3 * [Y] 10-52

DOI:   http://dx.doi.org/10.1126/science.186.4162.456
 [Y]  - MINTON N P ET AL, "Chemotherapeutic tumour targeting using clostridial spores", FEMS MICROBIOLOGY REVIEWS, ELSEVIER, AMSTERDAM, NL, (1995), vol. 17, no. 3, ISSN 0168-6445, pages 357 - 364, XP002242524 [Y] 10-52 * page 358, column 1, paragraph 2 - column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/0168-6445(95)00009-2
 [Y]  - MINTON N P ET AL, "Clostridia in Cancer Therapy", IN: BAHL H AND DÜRRE P EDITORS, CLOSTRIDIA - BIOTECHNOLOGY AND MEDICAL APPLICATIONS, WILEY-VCH, WEINHEIM, ISBN 3-527-30175-5, (20010215), pages 251 - 270, XP001247867 [Y] 10-52 * page 251 - page 254, paragraph 2 * * page 255, paragraph 4 - page 256, paragraph 2 *
 [XY]  - THEYS J ET AL, "IMPROVEMENT OF CLOSTRIDIUM TUMOUR TARGETING VECTORS EVALUATED IN RAT RHABDOMYOSARCOMAS", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, (200102), vol. 30, no. 1, ISSN 0928-8244, pages 37 - 41, XP001097591 [X] 38,40,43-50 * abstract * * page 40, column 2, paragraph 1 - page 41, column 1, paragraph 3 * [Y] 10-52

DOI:   http://dx.doi.org/10.1016/S0928-8244(00)00231-5
 [XA]  - HATHEWAY C L, "Toxigenic clostridia.", CLINICAL MICROBIOLOGY REVIEWS. JAN 1990, (199001), vol. 3, no. 1, ISSN 0893-8512, pages 66 - 98, XP002408674 [X] 1,4,5 * page 83, column 2, paragraph 2 * * page 83; table 7 * * page 68; table 1 * * page 82, column 1, paragraph 3 - page 84, column 2, paragraph 6 * [A]
International search[XP]  - DANG LONG H., "Combination bacteriolytic therapy for the treatment of experimental tumors", PROC. NATL. ACAD. SCI. USA, (20011218), vol. 98, no. 26, pages 15155 - 15160, XP003010304

DOI:   http://dx.doi.org/10.1073/pnas.251543698
Examination   - DANG LONG H ET AL, "Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents", CANCER BIOLOGY AND THERAPY, LANDES BIOSCIENCE, US, (20040301), vol. 3, no. 3, pages 326 - 337, XP002483666
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.